The acetabular fossa hot spot on 18F-FDG PET/CT: epidemiology, natural history, and proposed etiology

Skeletal Radiol. 2015 Jan;44(1):107-14. doi: 10.1007/s00256-014-2011-6. Epub 2014 Oct 7.

Abstract

Objective: To describe a benign focus of increased activity in the acetabular fossa (the acetabular fossa hot spot, AFHS) on (18) F-FDG PET/CT that can mimic a neoplasm.

Materials and methods: (18)F-FDG PET/CT images from four patient populations were examined. Group 1 (n = 13) was collected from a search of radiology reports and used to define the AFHS and for hypothesis generation. Group 2 (n = 1,150) was used for prevalence of AFHS. Group 3 (n = 1,213) had PET/CT and MRI pelvis within a week of each other and was used to correlate metabolic and anatomic findings. Group 4 (n = 100) was used to generate the control group. Data were collected on demographics, common comorbidities, underlying cancer diagnosis and status, and hip symptoms.

Results: Prevalence of AFHS was 0.36 % (95 % CI 0.10-0.91 %). None progressed to malignancy or was associated with cancer status. The majority (71 %) were on the left, and 6 % were bilateral. Mean SUVmax of the AFHS was 4.8 (range, 2.7-7.8). Male patients were more likely to have the AFHS (OR = 8.69, 95 % CI 1.88-40.13). There was no difference with respect to other collected data, including hip symptoms. Average minimum duration of AFHS was 346 days (range, 50-1,010 days). Readers did not detect corresponding hip abnormalities on MRIs.

Conclusions: AFHS is a benign finding that may be caused by subclinical ligamentum teres injury, focal synovitis, or degeneration of acetabular fossa fat. Despite uncertainty regarding its etiology, recognition of AFHS as a benign finding can prevent morbidity associated with unnecessary biopsy or initiation of therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetabulum / diagnostic imaging*
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / epidemiology*
  • False Positive Reactions
  • Fluorodeoxyglucose F18
  • Humans
  • Incidence
  • Joint Diseases / diagnosis*
  • Joint Diseases / epidemiology*
  • Middle Aged
  • Multimodal Imaging / statistics & numerical data
  • Positron-Emission Tomography / statistics & numerical data*
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Risk Assessment
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed / statistics & numerical data
  • United States / epidemiology
  • Young Adult

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18